Trial Profile
A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Dendritic cell vaccines (Primary) ; Interferon-alpha-2 (Primary) ; Rintatolimod (Primary) ; Ipilimumab; Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Mar 2024 Planned initiation date changed to 1 May 2024.
- 29 Jan 2024 Status changed from suspended to recruiting.
- 29 Nov 2023 Planned End Date changed from 22 Oct 2025 to 22 Dec 2025.